Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noad199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Malcolm F McDonald und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and The Brain Tumor Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: MicroRNAs, Glioblastoma, Exosomes, Brain Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Background
Glioblastoma (GBM) has poor prognosis due to ineffective agents and poor delivery methods. MicroRNAs (miRs) have been explored as novel therapeutics for GBM, but the optimal miRs and the ideal delivery strategy remain unresolved. In this study, we sought to identify the most effective pan-subtype anti-GBM miRs and to develop an improved delivery system for these miRs.
Methods
We conducted an unbiased screen of over 600 miRs against 7 glioma stem cell (GSC) lines representing all GBM subtypes to identify a set of pan-subtype-specific anti-GBM miRs and then used available TCGA GBM patient outcomes and miR expression data to hone in on miRs that were most likely to be clinically effective. To enhance delivery and expression of the miRs, we generated a polycistronic plasmid encoding 3 miRs (pPolymiR) and used HEK293T cells as biofactories to package pPolymiR into engineered exosomes (eExos) that incorporate viral proteins (Gag/VSVg) in their structure (eExos+pPolymiR) to enhance function.
Results
Our stepwise screen identified miR-124-2, miR-135a-2, and let-7i as the most effective miRs across all GBM subtypes with clinical relevance. Delivery of eExos+pPolymiR resulted in high expression of all 3 miRs in GSCs, and significantly decreased GSC proliferation in vitro. eExos+pPolymiR prolonged survival of GSC-bearing mice in vivo when compared with eExos carrying each of the miRs individually or as a cocktail. Conclusion eExos+pPolymiR, which includes a pan-subtype anti-glioma-specific miR combination encoded in a polycistronic plasmid and a novel exosome delivery platform, represents a new and potentially powerful anti-GBM therapeutic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery and The Brain Tumor Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- University of Texas MD Anderson Cancer Center
- The Broach Foundation for Brain Cancer Research
- The Elias Family Fund
- The Jason and Priscilla Hiley Fund
- The Bauman Family Curefest Fund
- Chuanwei Lu Fund
Zitieren
APA
McDonald, M. F., Hossain, A., Momin, E. N., Hasan, I., Singh, S., Adachi, S., Gumin, J., Ledbetter, D., Yang, J., Long, L., Daou, M., Gopakumar, S., Phillips, L. M., Parker Kerrigan, B., & Lang, F. F. (2024). Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad199
Vancouver
McDonald MF, Hossain A, Momin EN, Hasan I, Singh S, Adachi S, et al. Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad199
BibTeX
@article{McDonald2024,
author = {McDonald, Malcolm F and Hossain, Anwar and Momin, Eric N and Hasan, Irtiza and Singh, Sanjay and Adachi, Satoshi and Gumin, Joy and Ledbetter, Daniel and Yang, Jing and Long, Lihong and Daou, Marc and Gopakumar, Sricharan and Phillips, Lynette M and Parker Kerrigan, Brittany and Lang, Frederick F},
title = {Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noad199}
}
EUVIMED